AKRO - Akero Therapeutics - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

1.877B

Cash

343.2M

Avg Qtr Burn

-23.57M

Short % of Float

9.56%

Insider Ownership

8.30%

Institutional Own.

Qtr Updated

03/31/23

Drug Pipeline

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Efruxifermin (FGF-21 mimetic) Details Non-alcoholic steatohepatitis Big Mover™ Suspected Mover™ Susp. Mover™	Phase 2b Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Efruxifermin (FGF-21 mimetic) Details Non-alcoholic steatohepatitis Big Mover™ Suspected Mover™ Susp. Mover™	Phase 2b Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.